Roberto Piva

Roberto Piva

Turin, 10126, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications

Correction: Audrito et al. NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma. Cancers 2020, 12, 3855.

Correction: Audrito et al. NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma. Cancers 2020, 12, 3855.

Journal: Cancers
Published: July 06, 2026

Rapid minigene workflow for functional reclassification of splicing variants in hereditary cancer diagnostics.

Rapid minigene workflow for functional reclassification of splicing variants in hereditary cancer diagnostics.

Journal: Journal of medical genetics
Published: April 17, 2026

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

Journal: Cells
Published: April 02, 2026

Author Correction: Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.

Author Correction: Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.

Journal: Nature medicine
Published: March 21, 2026

Dual Targeting of IDH2 and the Ubiquitin-Proteasome System Reveals a Functional Vulnerability in Breast Cancer Models.

Dual Targeting of IDH2 and the Ubiquitin-Proteasome System Reveals a Functional Vulnerability in Breast Cancer Models.

Journal: Cancers
Published: December 23, 2025

Identification of ceRNA Regulatory Networks Driven by the lncRNA NEAT1 in Multiple Myeloma.

Identification of ceRNA Regulatory Networks Driven by the lncRNA NEAT1 in Multiple Myeloma.

Journal: Journal of cellular and molecular medicine
Published: October 28, 2025

Common genomic and transcriptomic signatures in Richter transformation highlight druggable vulnerabilities and guide drug repurposing strategies.

Common genomic and transcriptomic signatures in Richter transformation highlight druggable vulnerabilities and guide drug repurposing strategies.

Journal: Leukemia
Published: October 08, 2025

Correction: Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.

Correction: Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.

Journal: Experimental hematology & oncology
Published: June 13, 2025

Unlocking the Therapeutic Potential of Algae-Derived Compounds in Hematological Malignancies.

Unlocking the Therapeutic Potential of Algae-Derived Compounds in Hematological Malignancies.

Journal: Cancers
Published: December 21, 2024

IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition.

IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition.

Journal: Cancers
Published: August 26, 2024

Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma.

Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma.

Journal: Haematologica
Published: March 22, 2024

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.

Journal: Cell reports. Medicine
Published: July 22, 2023
Showing 1-12 of 61

Last Updated: 09/26/2026